Blog
RSS FeedPosted by Michael Wonder on 17 Oct 2025
Rare cancer lifeline comes with dual drug discounts
17 October 2025 - Two common immunotherapy drugs will now be subsidised for all advanced or metastatic cancers, providing a ...
Posted by Michael Wonder on 17 Oct 2025
Immunotherapy for patients with advanced cancers
17 October 2025 - More Australians living with advanced cancer could have access to immunotherapy treatment options, thanks to a ...
Posted by Michael Wonder on 16 Oct 2025
Recommendations made by the PBAC - September 2025
17 October 2025 - Recommendations made by the PBAC in September 2025 relating to the listing of medicines on the PBS ...
Posted by Michael Wonder on 04 Oct 2025
Engaging stakeholders along health technology assessment pathways: a scoping review of international practice
30 September 2025 - Health technology assessment has been characterised as a complex adaptive system that centrally features stakeholder interactions. ...
Posted by Michael Wonder on 12 Sep 2025
Public Summary Documents (first time decisions not to recommend and deferrals) – May 2025 PBAC meeting
12 September 2025 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the May 2025 PBAC ...
Posted by Michael Wonder on 05 Sep 2025
DoH publishes agenda for November 2025 PBAC meeting (version 3)
5 September 2025 - The DoH has published a revised agenda for the November 2025 PBAC meeting. ...
Posted by Michael Wonder on 02 Sep 2025
DoH publishes revised agenda for September 2025 PBAC meeting (version 2)
2 September 2025 - The agenda for the September 2025 PBAC meeting has now been updated. ...
Posted by Michael Wonder on 29 Aug 2025
Public Summary Documents – May 2025 PBAC meeting
29 August 2025 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the May 2025 PBAC ...
Posted by Michael Wonder on 29 Aug 2025
Agenda for the September 2025 PBAC intracycle meeting
29 August 2025 - The agenda for the September 2025 PBAC intracycle meeting is now available. ...
Posted by Michael Wonder on 25 Aug 2025
Bewildering PBAC decision a missed opportunity to ensure Australian cancer patients not left behind
23 August 2025 - MSD Australia & New Zealand is astonished that after eight years of dialogue and consideration, the ...
Posted by Michael Wonder on 25 Aug 2025
Recommendations made the PBAC – July 2025
22 August 2025 - The recommendations from the July 2025 PBAC meeting are now available. ...
Posted by Michael Wonder on 25 Aug 2025
Committee rejects application for medication Keytruda to be subsidised for Aussies with cancer
23 August 2025 - Australians with rare cancers like Natalie Willacy have just been handed a devastating hit, which could leave ...
Posted by Michael Wonder on 25 Aug 2025
Injectable form of Ocrevus for relapsing remitting multiple sclerosis recommended for PBS listing
22 August 2025 - This new form of ocrelizumab is given as an injection under the skin (subcutaneously), takes a much ...
Posted by Michael Wonder on 24 Aug 2025
New Alzheimer’s drug rejected for PBS listing, leaving patients to pay up to $80k a year
23 August 2025 - New Alzheimer’s drug rejected for PBS listing, leaving patients to pay up to $80k/year. ...
Posted by Michael Wonder on 22 Aug 2025
DoH publishes revised agenda for November 2025 PBAC meeting (version 2)
20 August 2025 - The DoH has published a revised agenda for the November 2025 PBAC meeting. ...